Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity | Zendy

Deborah Siegal | Zendy; John T. Curnutte | Zendy; Stuart J. Connolly | Zendy; Genmin Lu | Zendy; Pamela B. Conley | Zendy; Brian L. Wiens | Zendy; Vandana Mathur | Zendy; Janice Castillo | Zendy; Michele Bronson | Zendy; Janet M. Leeds | Zendy; F. Mar | Zendy; Alex Gold | Zendy; Mark Crowther | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity

Author(s) -

Deborah Siegal,

John T. Curnutte,

Stuart J. Connolly,

Genmin Lu,

Pamela B. Conley,

Brian L. Wiens,

Vandana Mathur,

Janice Castillo,

Michele Bronson,

Janet M. Leeds,

F. Mar,

Alex Gold,

Mark Crowther

Publication year - 2015

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1510991

Subject(s) - rivaroxaban , medicine , apixaban , placebo , bolus (digestion) , prothrombin complex concentrate , liter , anesthesia , anticoagulant , warfarin , atrial fibrillation , alternative medicine , pathology

Bleeding is a complication of treatment with factor Xa inhibitors, but there are no specific agents for the reversal of the effects of these drugs. Andexanet is designed to reverse the anticoagulant effects of factor Xa inhibitors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research